Please assess the completion status of the following clinical trial:

Trial Title: Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cancer, admitted for myelosupppresive stem cell transplantation. Included preparative regimens include: TBI/VP16/CY, TBI/CY, BU/CY (PO \& IV), and BCV~* Age 18 or older~* Alcohol intake \<100 gm/d for the last year (\< approximately 5 drinks per day)~* Renal function: estimated or measured CrCl 50 ml/min~* Liver function: T.Bili \<1.5, AST \< 2x ULN, unless due to disease~* Able to swallow tablets and capsules~Exclusion Criteria:~* Age \< 18~* High alcohol intake \[\> 100 gm/d in the last year\]~* Allergy or intolerance to: ondansetron or dexamethasone~* Renal dysfunction \[measured or estimated CrCl \< 50 ml/min\]~* Liver dysfunction \[T.Bili \> 1.5, AST \> 2x ULN, unless due to disease\]~* Inability to swallow tablets or capsules~* Concurrent condition requiring systemic steroid use~* Nonmyeloablative SCT, patients receiving the conditioning regimens not included \[see inclusion criteria\]~* History of anticipatory nausea and vomiting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard PO (Zofran + Dexamethasone) (Type: PLACEBO_COMPARATOR): Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron (Zofran) 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion.
- Aprepitant (MK-869) + Standard PO (Type: ACTIVE_COMPARATOR): Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO \[blinded\] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO \[blinded\] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).